2016 Jeffrey M. Hoeg Award Lecture
- PMID: 29930003
- DOI: 10.1161/ATVBAHA.118.307742
2016 Jeffrey M. Hoeg Award Lecture
Abstract
Innate and adaptive immune effector mechanisms, in conjunction with hyperlipidemia, are important drivers of atherosclerosis. The interaction between the different immune cells and the secretion of cytokines and chemokines determine the progression of atherosclerosis. The activation or dampening of the immune response is tightly controlled by immune checkpoints. Costimulatory and coinhibitory immune checkpoints represent potential targets for immune modulatory therapies for atherosclerosis. This review will discuss the current knowledge on immune checkpoints in atherosclerosis and the clinical potential of immune checkpoint targeted therapy for atherosclerosis.
Keywords: atherosclerosis; chemokines; cytokines; hyperlipidemia; mice.
Similar articles
-
Exploring immune checkpoints as potential therapeutic targets in atherosclerosis.Cardiovasc Res. 2018 Mar 1;114(3):368-377. doi: 10.1093/cvr/cvx248. Cardiovasc Res. 2018. PMID: 29309533 Review.
-
Atherosclerosis and immunity: A perspective.Trends Cardiovasc Med. 2019 Aug;29(6):363-371. doi: 10.1016/j.tcm.2018.09.017. Epub 2018 Sep 28. Trends Cardiovasc Med. 2019. PMID: 30292470 Review.
-
Inflammation and atherosclerosis: what is on the horizon?Heart. 2020 Jan;106(1):80-85. doi: 10.1136/heartjnl-2018-314230. Heart. 2020. PMID: 31843811 Review. No abstract available.
-
Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities.Atherosclerosis. 2018 Sep;276:1-9. doi: 10.1016/j.atherosclerosis.2018.07.007. Epub 2018 Jul 6. Atherosclerosis. 2018. PMID: 30006321 Review.
-
Targeting the immune response in atherosclerosis: It's time for clinical trials!Arch Cardiovasc Dis. 2017 Dec;110(12):643-645. doi: 10.1016/j.acvd.2017.08.001. Epub 2017 Oct 16. Arch Cardiovasc Dis. 2017. PMID: 29051009 No abstract available.
Cited by
-
Updates on Approaches for Studying Atherosclerosis.Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):e108-e117. doi: 10.1161/ATVBAHA.119.312001. Arterioscler Thromb Vasc Biol. 2019. PMID: 30917052 Free PMC article. No abstract available.
-
Biological drug and drug delivery-mediated immunotherapy.Acta Pharm Sin B. 2021 Apr;11(4):941-960. doi: 10.1016/j.apsb.2020.12.018. Epub 2020 Dec 31. Acta Pharm Sin B. 2021. PMID: 33996408 Free PMC article. Review.
-
Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease.Nat Commun. 2021 Jun 18;12(1):3754. doi: 10.1038/s41467-021-23909-z. Nat Commun. 2021. PMID: 34145241 Free PMC article.
-
Costimulatory and Coinhibitory Immune Checkpoints in Atherosclerosis: Therapeutic Targets in Atherosclerosis?JACC Basic Transl Sci. 2024 Mar 13;9(6):827-843. doi: 10.1016/j.jacbts.2023.12.007. eCollection 2024 Jun. JACC Basic Transl Sci. 2024. PMID: 39070270 Free PMC article. Review.
-
The emerging role of Th1 cells in atherosclerosis and its implications for therapy.Front Immunol. 2023 Jan 5;13:1079668. doi: 10.3389/fimmu.2022.1079668. eCollection 2022. Front Immunol. 2023. PMID: 36685487 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
